Immunogenomics Facility
- Overview: The Leeds Immunogenomics Facility (IGF) is a research facility in the Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM). Our services are available to researchers from the University of Leeds, as well as external users from academia and industry. We use Olink® proteomics technology for targeted protein biomarker research, providing new insights into disease, improving disease detection and helping to understand disease biology.
Welcome to the Leeds Immunogenomics Facility (IGF)
UK’s First Certified Core Facility to Run Olink® Mid-Plex Assays
We use Olink® proteomics technology for targeted protein biomarker research, providing new insights into disease, improving disease detection and helping to understand disease biology. Having been early adopters of the Olink® Proteomics platform in-house for our own biomarker research, we have gained extensive experience which we now offer to external academic groups and industry.
Why Olink?
• Rapid, high-throughput protein analysis
• Curated panels of protein biomarkers
• Compatible with a wide range of sample types
• Exceptional sensitivity and specificity
• Uses only 1ul of biological sample
• Strict assay technical validation and quality control procedures
• Click here to view rapidly growing list of publications
Contact us at IGF@leeds.ac.uk for advice on:
• Project study design
• Costs/estimates for grant applications
• Quotations for your project
Olink® PEA Technology
Next-Gen Technology for Highly Accurate, Multiplex Protein Analysis
Olink utilises proprietary Proximity Extension Assay (PEA) technology, which combines immunoaffinity with a qPCR readout to measure proteins with exceptional throughput, sensitivity, and specificity.
Paired antibodies conjugated to complementary oligonucleotide sequences come in close proximity only when they both bind to their specific target protein (see Figure 1 below).
The complementary oligonucleotides hybridize, creating a unique double-stranded barcode for the protein and sample, and subsequently extended and amplified via PCR. For Olink® mid-plex assays, the amplicons are measured using qPCR on the Olink® Signature Q100 and are quantitatively proportional to the initial concentration of the target protein.
The cycle threshold (Ct) values generated from qPCR are translated into relative quantification units known as Normalised Protein eXpression (NPX) values using a series of computations, which minimise technical variation and improve interpretability of results. Importantly, the technical performance of the assay is ascertained using a built-in QC system using internal, spiked-in controls.
Figure 1. Olink® Target enables protein measurement with a qPCR -antibodies hybridize upon antigen binding. The hybridized oligonucleotide is amplified via PCR, and the resulting amplicons are measured using microfluidic qPCR on the Olink® Signature Q100 benchtop instrument. ©Olink Proteomics AB.
Watch a 3-minute animation of Olink PEA technology: ©Olink Proteomics AB :
Olink® Target 48 and 96
Innovative Platform for Human Protein Biomarker Discovery, Development and Validation
Target 48
• Choose from 2 available cytokine panels, human or mouse
• Simultaneous analysis of 45 protein biomarkers for up to 42 samples
• Targets proteins (i.e., cytokines) associated with inflammation
• Uses only 1 µL per biological sample
• Results reported in standard concentration units (pg/mL) or relative quantification (NPX units)
Target 96
• Choose from 15 carefully designed panels available for human (14) and mouse (1)
• Each panel is focused on a specific area of disease or key biological process
• Broad library of over 1100 established or exploratory protein biomarkers
• Measurement of 92 protein biomarkers simultaneously for up to 88 samples with each panel
• Uses only 1 µL of biological sample per panel
• Results provided in Normalised Protein eXpression (NPX) values (i.e., relative quantification)
Click on the panels listed below to see the protein assay list and validation data:
| Panel assay list | Validation data |
|
Olink Target 48 Cytokine Panels |
|
|
Olink Target 96 Cardiovascular Panels |
|
|
Olink Target 96 Immuno-Oncology Panels |
|
|
Olink Target 96 Neurology Panels |
|
|
Olink Target 96 Oncology Panels |
|
|
Olink Target 96 Inflammation Panel |
|
|
Olink Target 96 Biological Processes Panels |
Organ Damage Development Metabolism |
Olink® Flex and Focus
Customizable made-to-order panels to suit your project needs
Flex
- Semi-customizable panel
- Choose from between 5 to 30 proteins from a library of ≈ 200 pre-validated proteins biomarkers
- Run up to 40 samples per panel
- Read-out in absolute quantification (pg/ml)
- Uses just 1ul of biological sample
- View the full list of Flex proteins and validation data here
Focus
- Fully customizable panel for specific and exclusive studies
- Expert help provided to design and thoroughly validate a bespoke panel to combine up to 21 biomarkers of your choice
- Minimum number of samples required is 1000
- Each kit accommodates 144 or 166 samples depending on whether data output is in relative NPX units of absolute quantification (pg/ml)
- Minimum sample volume of 1ul required
- Find out more about Olink’s custom Focus panel offering here
Contact Us
Please follow this link to contact us, stating your name, company / Institution and message and we will respond shortly.